Discover how long-time StartUp Health community member Sen-Jam Pharmaceutical is revolutionizing healthcare through groundbreaking anti-inflammatory solutions that could bridge the critical gap between lifespan and healthspan. In this StartUp Health NOW episode, co-founders Jim and Jackie Iversen share their journey in developing innovative medications targeting inflammation – the hidden culprit behind numerous age-related diseases and conditions The episode highlights their impressive progress, including: – Phase two clinical trials at Duke University – Positive outcomes in COVID patient studies – 60+ patents in their portfolio – Novel approach to alcohol-related inflammation – Promising collaboration with the National Institute of Drug Abuse Intriguingly, their research extends beyond traditional applications, showing potential in enhancing GLP-1 medications and addressing substance use disorders through neuroinflammation reduction. The team’s vision shifts healthcare from reactive “sick care” to proactive health solutions, promising more affordable and accessible medications for long-term use. Ready to explore the future of preventative healthcare? Tune in to hear how Sen-Jam’s innovations could transform the way we approach aging and chronic illness management. Are you ready to tell YOUR story? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world’s biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, magazine, and YouTube channel – is a benefit of our Health Moonshot PRO Membership . To schedule a call and see if you qualify to join and increase brand awareness through our multi-media storytelling efforts, submit our three-minute application. If you’re mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit. » Learn more and apply today . Want more content like this? Sign up for StartUp Health Insider ™ to get funding insights, news, and special updates delivered to your inbox.
